FDA Alerts

The FDA has approved new options for the treatment of seasonal influenza, squamous non-small cell lung cancer, and for the prevention of anthrax disease.

You frequently see the word “Natural” on food packaging, but what does it mean? Probably not what you think it does. And the FDA has decided it’s time—maybe—to legally define the term, and enforce rules...

The FDA approved ustekinumab-auub as an interchangeable biosimilar with ustekinumab for multiple inflammatory diseases.

The FDA has approved a new, daily, fixed-dose combination therapy for HIV treatment, and a new add-on treatment for severe, poorly-controlled asthma.

The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.

The FDA has approved new options for the treatment of patients with hyperkalemia, metastatic pancreatic cancer, and hereditary Factor X deficiency.

The FDA has approved new options for schizophrenia and non-small cell lung cancer, as well as a cerebrospinal fluid test for the detection of various pathogens.

The FDA has approved 2 new drugs for the improvement of blood glucose control in patients with type 1 and type 2 diabetes mellitus.

The FDA has approved a new drug for colorectal cancer, a new test for influenza, and issued a warning of dose confusion with a combination antibacterial drug.